LAKE ZURICH, Ill.--(BUSINESS WIRE)--Fresenius Kabi announced today it will introduce a portfolio of generic contrast media agents in the United States, starting immediately with the launch of ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. 53% of patients with an iodinated contrast allergy and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback